There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Amarin (AMRN) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on BioMarin Pharmaceutical on December 23 and set a price target of $95.00. The company’s shares closed last Monday at $79.17.
According to TipRanks.com, Gilson is a 5-star analyst with an average return of 38.3% and a 66.0% success rate. Gilson covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Sigilon Therapeutics, and Stoke Therapeutics.
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $109.22, a 38.6% upside from current levels. In a report issued on December 17, J.P. Morgan also maintained a Buy rating on the stock with a $131.00 price target.
See today’s analyst top recommended stocks >>
Amarin (AMRN)
Leerink Partners analyst Ami Fadia maintained a Buy rating on Amarin on February 1 and set a price target of $16.00. The company’s shares closed last Monday at $6.19.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of 6.7% and a 51.1% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Amarin is a Strong Buy with an average price target of $11.00, representing a 59.0% upside. In a report issued on January 22, Cowen & Co. also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
